Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Brewer

Family Medicine Forrest, IL Medical Doctor

NPI 1184618258 CMS profile 189381

122 E Wabash Ave, Forrest, IL 61741

Open in the dashboard

General payments

$13,196

420 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Brewer of Forrest, IL is reported in the CMS Open Payments database as having received $13,196 across 420 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,670 75
2024 General $2,487 89
2023 General $4,686 58
2022 General $2,229 60
2021 General $1,040 51
2020 General $596 53
2019 General $489 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Brewer
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Benjamin Brewer were reported at $1,670. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Benjamin Brewer Family Medicine median Middle half National median
2019 $489 $150 $41–$543 $163
2020 $596 $120 $32–$415 $114
2021 $1,040 $137 $35–$551 $132
2022 $2,229 $137 $37–$512 $149
2023 $4,686 $149 $42–$545 $160
2024 $2,487 $156 $44–$560 $164
2025 $1,670 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $6,047 99 payments
  2. Allergan Inc. $2,775 49 payments
  3. Novo Nordisk Inc $688 51 payments
  4. Radius Health, Inc. $389 20 payments
  5. Merck Sharp & Dohme Corporation $381 28 payments
  6. GlaxoSmithKline, LLC. $305 26 payments
  7. Pfizer Inc. $263 16 payments
  8. Aimmune Therapeutics, Inc. $233 10 payments
  9. Novartis Pharmaceuticals Corporation $217 9 payments
  10. Amgen Inc. $199 13 payments
  11. Other $1,700 99 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,654 28 payments
  2. Food and Beverage $6,533 391 payments
  3. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. BOTOX $889 42 payments
  2. Ozempic $591 42 payments
  3. VRAYLAR $454 29 payments
  4. Tymlos $373 19 payments
  5. ZENPEP $281 13 payments
  6. RYBELSUS $238 18 payments
  7. VERQUVO $203 14 payments
  8. STEGLATRO $191 15 payments
  9. EVENITY $187 12 payments
  10. LEQVIO $184 7 payments
  11. Other $4,132 269 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 149 drugs

Part D claims

7,227

Median for Family Practice: 1,826

Drug cost

$814,796

Median for Family Practice: $120,094

Branded share of claims

27%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 274 $138,910
Ozempic Semaglutide Brand 131 $123,353
Jardiance Empagliflozin Brand 108 $94,297
Vraylar Cariprazine Hcl Brand 39 $53,342
Mounjaro Tirzepatide Brand 31 $47,739
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 59 $33,858
Trulicity Dulaglutide Brand 22 $29,762
Zenpep Lipase/Protease/Amylase Brand 13 $25,174
Nuedexta Dextromethorphan Hbr/Quinidine Brand 23 $17,922
Aripiprazole Generic 32 $14,980

The 10 drugs with the highest cost, of 149 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $280
$280 — —
VRAYLAR
  • AbbVie, Inc. $151
$151 39 —
Tymlos
  • Radius Health, Inc. $116
$116 — —
Ozempic
  • Novo Nordisk Inc $89
$89 131 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

420 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record